SCHEMBL13041793

SCHEMBL13041793

Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)cc(C3CC3)nc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.54
FLT3 P36888 7/20 0.54
KIT P10721 7/20 0.54
CSF1R P07333 7/20 0.54
LCK P06239 6/20 0.54
FLT1 P17948 6/20 0.54
FLT4 P35916 6/20 0.54
BLK P51451 5/20 0.54
LYN P07948 4/20 0.54
SRC P12931 3/20 0.54
ABL1 P00519 2/20 0.54
FYN P06241 2/20 0.52
NTRK2 Q16620 4/20 0.49
ROCK2 O75116 3/20 0.49
MAP4K4 O95819 3/20 0.49
FGFR1 P11362 3/20 0.49
CSNK1A1 P48729 3/20 0.49
CSNK1D P48730 3/20 0.49
IRAK1 P51617 3/20 0.49
CSNK1G2 P78368 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041798 0.93 KDR (0.54) KDRFLT3KITCSF1RLCK
SCHEMBL13041752 0.89 KDR (0.54) KDRFLT3KITCSF1RLCK
SCHEMBL13041796 0.89 KDR (0.58) KDRFLT3KITCSF1RLCK
SCHEMBL13041755 0.89 CSF1R (0.53) KDRFLT3KITCSF1RLCK
SCHEMBL13041799 0.88 KDR (0.70) KDRFLT3KITCSF1RLCK
SCHEMBL13041778 0.88 KIT (0.52) KDRFLT3KITCSF1RLCK
SCHEMBL13041764 0.87 KDR (0.51) KDRFLT3KITCSF1RLCK
SCHEMBL2821104 0.87 KDR (0.70) KDRFLT3KITCSF1RLCK
SCHEMBL13041795 0.86 KDR (0.54) KDRFLT3KITCSF1RLCK
SCHEMBL13041850 0.86 KDR (0.48) KDRFLT3KITCSF1RLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
WO-2007144202-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO disclosed
EP-1867647-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK KDR 1/4885FLT3 116/4885KIT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.